113 related articles for article (PubMed ID: 20126993)
1. Proteomic characterization of the cellular response to chemopreventive triterpenoid astragaloside IV in human hepatocellular carcinoma cell line HepG2.
Qi H; Wei L; Han Y; Zhang Q; Lau AS; Rong J
Int J Oncol; 2010 Mar; 36(3):725-35. PubMed ID: 20126993
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of hepatocellular carcinoma HepG2 cells treated with platycodin D.
Lu JJ; Lu DZ; Chen YF; Dong YT; Zhang JR; Li T; Tang ZH; Yang Z
Chin J Nat Med; 2015 Sep; 13(9):673-9. PubMed ID: 26412427
[TBL] [Abstract][Full Text] [Related]
3. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling.
Jiang K; Lu Q; Li Q; Ji Y; Chen W; Xue X
Int Immunopharmacol; 2017 Jan; 42():195-202. PubMed ID: 27930970
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Inhibitory Effect of Traditional Chinese Medicine Astragaloside IV and Curcumin on Tumor Growth and Angiogenesis in an Orthotopic Nude-Mouse Model of Human Hepatocellular Carcinoma.
Zhang S; Tang D; Zang W; Yin G; Dai J; Sun YU; Yang Z; Hoffman RM; Guo X
Anticancer Res; 2017 Feb; 37(2):465-473. PubMed ID: 28179291
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV enhances cisplatin chemosensitivity in hepatocellular carcinoma by suppressing MRP2.
Qu X; Gao H; Zhai J; Sun J; Tao L; Zhang Y; Song Y; Hu T
Eur J Pharm Sci; 2020 May; 148():105325. PubMed ID: 32259679
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV inhibits cell migration and viability of hepatocellular carcinoma cells via suppressing long noncoding RNA ATB.
Li Y; Ye Y; Chen H
Biomed Pharmacother; 2018 Mar; 99():134-141. PubMed ID: 29331759
[TBL] [Abstract][Full Text] [Related]
7. Astragaloside IV Induces Apoptosis, G
Su CM; Wang HC; Hsu FT; Lu CH; Lai CK; Chung JG; Kuo YC
In Vivo; 2020; 34(2):631-638. PubMed ID: 32111763
[TBL] [Abstract][Full Text] [Related]
8. Liquid chromatography-mass spectrometry-based quantitative proteomics analysis reveals chondroprotective effects of astragaloside IV in interleukin-1β-induced SW1353 chondrocyte-like cells.
Luo H; Yao L; Zhang Y; Li R
Biomed Pharmacother; 2017 Jul; 91():796-802. PubMed ID: 28501006
[TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV inhibits metastasis in hepatoma cells through the suppression of epithelial-mesenchymal transition via the Akt/GSK-3β/β-catenin pathway.
Qin CD; Ma DN; Ren ZG; Zhu XD; Wang CH; Wang YC; Ye BG; Cao MQ; Gao DM; Tang ZY
Oncol Rep; 2017 Mar; 37(3):1725-1735. PubMed ID: 28112375
[TBL] [Abstract][Full Text] [Related]
10. Anti-hepatitis B virus activities of astragaloside IV isolated from radix Astragali.
Wang S; Li J; Huang H; Gao W; Zhuang C; Li B; Zhou P; Kong D
Biol Pharm Bull; 2009 Jan; 32(1):132-5. PubMed ID: 19122295
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3.
He CS; Liu YC; Xu ZP; Dai PC; Chen XW; Jin DH
Cell Physiol Biochem; 2016; 40(5):1221-1229. PubMed ID: 27960166
[TBL] [Abstract][Full Text] [Related]
12. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II.
Huang C; Xu D; Xia Q; Wang P; Rong C; Su Y
J Pharm Pharmacol; 2012 Dec; 64(12):1741-50. PubMed ID: 23146037
[TBL] [Abstract][Full Text] [Related]
13. Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells.
Li T; Xu WS; Wu GS; Chen XP; Wang YT; Lu JJ
Asian Pac J Cancer Prev; 2014; 15(4):1745-9. PubMed ID: 24641402
[TBL] [Abstract][Full Text] [Related]
14. Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy.
Wang M; Huang C; Su Y; Yang C; Xia Q; Xu DJ
J Pharm Pharmacol; 2017 Jun; 69(6):743-752. PubMed ID: 28266023
[TBL] [Abstract][Full Text] [Related]
15. Comparative proteomics and molecular mechanical analysis in CDA-II induced therapy of LCI-D20 hepatocellular carcinoma model.
Fan HZ; Liu H; Zhang C; Gao DM; Xue Q; Chen J; Sun RX; Liu YK; Yang PY
J Cancer Res Clin Oncol; 2009 Apr; 135(4):591-602. PubMed ID: 18853186
[TBL] [Abstract][Full Text] [Related]
16. Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study.
Ilyas A; Hashim Z; Channa IS; Zarina S
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):241-250. PubMed ID: 29627155
[TBL] [Abstract][Full Text] [Related]
17. Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts.
Wang ZF; Ma DG; Zhu Z; Mu YP; Yang YY; Feng L; Yang H; Liang JQ; Liu YY; Liu L; Lu HW
World J Gastroenterol; 2017 Dec; 23(48):8512-8525. PubMed ID: 29358859
[TBL] [Abstract][Full Text] [Related]
18. Genistein induces apoptosis by down-regulating thioredoxin-1 in human hepatocellular carcinoma SNU-449 cells.
Roh T; Kim SW; Moon SH; Nam MJ
Food Chem Toxicol; 2016 Nov; 97():127-134. PubMed ID: 27597132
[TBL] [Abstract][Full Text] [Related]
19. A proteomic analysis of mushroom polysaccharide-treated HepG2 cells.
Chai Y; Wang G; Fan L; Zhao M
Sci Rep; 2016 Mar; 6():23565. PubMed ID: 27020667
[TBL] [Abstract][Full Text] [Related]
20. Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma.
Tan Y; Qin S; Hou X; Qian X; Xia J; Li Y; Wang R; Chen C; Yang Q; Miele L; Wu Q; Wang Z
Curr Pharm Des; 2014; 20(1):81-7. PubMed ID: 23530500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
